Live
Will the FDA approve intismeran autogene (V940/mRNA-4157)? — intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma
Starts:Aug 19, 2026, 10:00 PMEnds:Jul 1, 2028, 3:59 AM
AZRGMIKSHLMTNVGPLYPMU
Total volume
$2.0K
Largest spread
—
Outcomes
5
Platforms
1
Markets
1
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Before Jan 1, 2028 Favorite | 81.0%Kalshi | $1.2K | — | — | — | — | — | — | |
Before Oct 1, 2027 | 64.0%Kalshi | $777 | — | — | — | — | — | — | |
Before Jan 1, 2028Favorite
81.0%Best · Kalshi$1.2K
Before Oct 1, 2027
64.0%Best · Kalshi$777
AI-generated summary, may be inaccurate.
A detailed summary of this event hasn't been generated yet. Once available, it will explain the context, key contenders, and what each outcome resolves to.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.